Dolutegravir [50 mg film-coated tablet] for treatment of treatment-naive and treatment-experienced adolescents and adults living with HIV
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 11 September 2021)
As final recommendation, the HTA Council recommends dolutegravir [50 mg film-coated tablet] for treatment of treatment-naive and treatment-experienced adolescents and adults living with HIV for government financing
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should dolutegravir [50 mg film-coated tablet] for treatment of treatment-naive and treatment-experienced adolescents and adults living with HIV be funded by the government?
- Secretary of Health Decision: Approved on 21 September 2021
Evidence and Relevant Documents